VistaGen Therapeutics Inc. VTGN Archives - Page 4 of 4

TuesdayNov 03, 2020 2:58 pm

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Stock2Me Podcast

VistaGen (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in the latest episode of The Stock2Me Podcast, an InvestorBrandNetwork (“IBN”) solution to provide specialized content distribution via widespread syndication channels. The episode features Shawn K. Singh, CEO of VistaGen, as he discusses the company’s innovative development pipeline and focus on bringing new, effective treatment options for anxiety, depression and other conditions involving the central nervous system (“CNS”) for which the company believes current treatment alternatives are inadequate, resulting in high unmet need. “Throughout the many years I’ve…

MondayNov 02, 2020 11:32 am

VistaGen Therapeutics Inc. (NASDAQ: VTGN) Preclinical Study Data Show Drug Combo’s Innovative Potential in Fight Against Major Depressive Disorder

Study results have exciting therapeutic potential across wide range of CNS indications. VTGN focused on developing new generation of medications to treat anxiety, depression and more. Company committed to finding treatment to help estimated 264 million people around the world who suffer from depression. Noting that 17.3 million adults in the United States have had at least one major depressive episode and some 264 million people around the world suffer from depression, VistaGen Therapeutics (NASDAQ: VTGN) is committed to finding effective treatments for depression that reach beyond the current standard of care, which includes oral antidepressants and oral atypical antipsychotics.…

FridayOct 30, 2020 11:06 am

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in BioWorld Article

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent BioWorld article titled, “CBC-funded Affamed merges with Everinsight, extends portfolio with Kissei PD candidate.” The publication discusses the merging of Affamed Therapeutics Ltd., an emerging biopharmaceutical company focused on opthamology markets in Greater China and funded by the large global venture capital firm, CBC Group, and EverInsight Therapeutics Inc., a biopharmaceutical company focused on central nervous system disorders and also funded by CBC Group. EverInsight and VistaGen entered into an exclusive development and commercialization…

ThursdayOct 08, 2020 3:21 pm

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) Featured in Research Report

VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was featured in a recent research report by Aegis Capital Corp. The report reads, “VistaGen is developing multiple therapeutic candidates for the treatment of anxiety, depression, and other CNS indications. VistaGen's development pipeline includes PH94B, a neuroactive nasal spray targeting Social Anxiety Disorder (‘SAD’), among other conditions, PH10, an additional neuroactive nasal spray for indications including Major Depressive Disorder (‘MDD’), and AV-101 an oral drug for psychiatric and other CNS disorders. We believe Phase 2 data in PH94B…

WednesdayOct 07, 2020 2:46 pm

QualityStocksNewsBreaks – Why VistaGen Therapeutics (NASDAQ: VTGN) Is ‘One to Watch’

VistaGen Therapeutics (NASDAQ: VTGN) is a biopharmaceutical company committed to developing and commercializing a new generation of medications that go beyond the standard of care for anxiety, depression and other central nervous system (“CNS”) disorders. Based out of South San Francisco, California, the “Birthplace of Biotechnology,” VistaGen is headquartered among the largest cluster of biotechnology companies in the world. A recent article discussing the company reads, “VistaGen currently has three innovative CNS drug candidates in its pipeline: PH94B, PH10 and AV-101. With a differentiated mechanism of action and an exceptional safety profile in all clinical studies to date, each of…

FridayOct 02, 2020 10:41 am

VistaGen Therapeutics Inc. (NASDAQ: VTGN) is “One to Watch”

VistaGen’s product portfolio consists of three novel drug candidates that, together, target multiple anxiety disorders, depression disorders and neurological disorders Two of the company’s drug candidates have received an FDA fast track designation, including for the treatment of social anxiety disorder, major depressive disorder and neuropathic pain. The global CNS therapeutics market is estimated to reach $130 billion by 2025 The two most common mental health conditions – anxiety and depression – cost the global economy an estimated $1 trillion each year VistaGen is committed to developing and commercializing multiple new generation medications that go beyond the standard of care…

ThursdayOct 01, 2020 9:55 am

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses ‘Sea of Change’ to Future of Anxiety Treatment

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Life Science Leader titled, “The Future of Anxiety Treatment Will Be Drastically Different.” In the piece, Singh, an experienced professional who has dedicated over 25 years to biopharma and medical device industries, addresses the current standard of care for anxiety disorders and its inability to meet the growing need. “As researchers learn more about psychological therapy for anxiety disorders and medication options to complement it, efforts are underway to develop innovative medications to displace current anti-anxiety drugs that are not effective for all patients and are associated with…

WednesdaySep 30, 2020 9:35 am

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Addresses ‘Multi-Pronged Approach’ to Growing Problem of Workplace Stress and Anxiety

VistaGen Therapeutics’ (NASDAQ: VTGN) CEO Shawn Singh authored a recent article for Business.com regarding the COVID-19 pandemic and resulting stress and anxiety impacts to the workplace. In the piece, Singh indicates that stress and anxiety, often driven by job-related issues, when left unchecked can rise to the level of an anxiety disorder with negative consequences for physical health, mental well-being, productivity and career opportunities. The global pandemic has exacerbated this largely unaddressed and widespread mental health problem in the workplace, markedly reflecting in increased prescriptions for antidepressant and anti-anxiety medications, many associated with significant side effects and safety concerns. “To…

TuesdaySep 29, 2020 2:52 pm

QualityStocksNewsBreaks – VistaGen Therapeutics (NASDAQ: VTGN) CEO Discusses PH94B Drug Candidate in Applied Clinical Trials Publication

VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines for anxiety, depression and other central nervous system (“CNS”) disorders, was recently featured in an Applied Clinical Trials article titled, “Pushing Late-Stage Treatments Forward in the Clinic.” In the article, VistaGen’s CEO Shawn Singh discussed the company's ongoing efforts to treat and help manage the anxiety symptoms provoked by COVID-19 and other triggers, anxiety-related disorders initially in subjects suffering from Social Anxiety Disorder (“SAD”), as well as the FDA’s consensus on the design of the company’s pivotal Phase III study of PH94B. The piece quotes Singh, who states, “Now…

WednesdayOct 10, 2018 12:27 pm

VistaGen Therapeutics, Inc. (NASDAQ: VTGN) Moves Forward in Developing As-Needed Treatment for Social Anxiety Disorder

Company signs a worldwide licensing agreement with Pherin Pharmaceuticals for the development and commercialization of a Phase 3-ready CNS drug candidate for as-needed treatment of social anxiety disorder Untreated social anxiety disorder has a significant impact on a person’s overall quality of life Clinical studies support the potential of PH94B to be a superior treatment alternative for SAD due to the demonstrated rapid onset of efficacy, route of administration, as-needed dosing convenience and excellent safety profile VistaGen Therapeutics, Inc. (NASDAQ: VTGN) is a clinical-stage biopharmaceutical company developing new generation medicines for depression and other central nervous system (CNS) diseases and…

Site Search

Company Search

Tag: VistaGen Therapeutics Inc. VTGN